2seventy bio Past Earnings Performance
Past criteria checks 0/6
2seventy bio's earnings have been declining at an average annual rate of -3.8%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 144.2% per year.
Key information
-3.8%
Earnings growth rate
14.4%
EPS growth rate
| Biotechs Industry Growth | 12.9% |
| Revenue growth rate | 144.2% |
| Return on equity | -53.7% |
| Net Margin | -172.8% |
| Next Earnings Update | 14 Aug 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How 2seventy bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 125 | -215 | 76 | -1 |
| 31 Dec 22 | 91 | -254 | 79 | 0 |
| 30 Sep 22 | 51 | -292 | 85 | 4 |
| 30 Jun 22 | 57 | -284 | 89 | 4 |
| 31 Mar 22 | 51 | -291 | 93 | -5 |
| 31 Dec 21 | 55 | -292 | 94 | 0 |
| 30 Sep 21 | 48 | -308 | 91 | 0 |
| 30 Jun 21 | 48 | -320 | 90 | 0 |
| 31 Mar 21 | 150 | -222 | 92 | 9 |
| 31 Dec 20 | 248 | -120 | 91 | 0 |
| 31 Dec 19 | 44 | -321 | 82 | 0 |
| 31 Dec 18 | 55 | -200 | 54 | 0 |
Quality Earnings: TSVT * is currently unprofitable.
Growing Profit Margin: TSVT * is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TSVT * is unprofitable, and losses have increased over the past 5 years at a rate of 3.8% per year.
Accelerating Growth: Unable to compare TSVT *'s earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TSVT * is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.8%).
Return on Equity
High ROE: TSVT * has a negative Return on Equity (-53.69%), as it is currently unprofitable.